# A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

> **NCT06331650** · PHASE2 · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** cadonilimab

## Key facts

- **NCT ID:** NCT06331650
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-09
- **Primary completion:** 2025-08
- **Final completion:** 2025-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331650, "A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06331650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*